ENDOLOGIX, INC. (NASDAQ:ELGX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Company) approved, subject to stockholder approval, an amendment
to the Companys 2015 Stock Incentive Plan (as amended, the Plan),
which was approved by the Companys stockholders at the 2017
annual meeting of stockholders held on May 31, 2017 (the Annual
Meeting). The Plan amendment increased the total number of shares
reserved for issuance under the Plan by 3,500,000 shares, or from
6,300,000 shares to 9,800,000 shares.
to be complete and is qualified in its entirety by reference to
the Plan, a copy of which is attached as Exhibit 10.1 to this
Current Report on Form 8-K (this Current Report) and is
incorporated herein by reference.
the Marriott Marquis San Diego Marina, 333 West Harbor Drive, San
Diego, California 92101. As of April 13, 2017, the record date
for the Annual Meeting, the Company had 82,969,076 shares of its
common stock outstanding and entitled to vote, of which
75,107,773 shares of the Companys common stock were present in
person or represented by proxy and entitled to vote at the Annual
Meeting. The following is a brief description of the final voting
results for each of the proposals submitted to a vote of the
stockholders at the Annual Meeting.
Class I nominees named below to serve on the Companys Board of
Directors for a three-year term expiring at the Companys 2020
annual meeting of stockholders and until their respective
successors are duly elected and qualified.
|
Class III Nominee
|
Votes For
|
Votes Withheld
|
Broker Non-votes
|
|
Daniel Lemaitre
|
64,956,795
|
868,185
|
9,282,793
|
|
Leslie Norwalk
|
65,367,529
|
457,451
|
9,282,793
|
advisory vote the compensation of the Companys named executive
officers as described in the proxy statement for the Annual
Meeting.
|
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
|
26,594,097
|
39,132,094
|
98,789
|
9,282,793
|
basis an annual frequency of future stockholder advisory votes on
the compensation of the Companys named executive officers.
|
Every Year
|
Every 2 Years
|
Every 3 Years
|
Votes Abstaining
|
|
65,539,310
|
30,416
|
240,801
|
14,453
|
Board of Directors of the Company has determined that future
stockholder advisory votes on the compensation of the Companys
named executive officers will occur every year.
to the Companys 2015 Stock Incentive Plan, as amended, increasing
the total number of shares reserved for issuance thereunder by
3,500,000 shares, or from 6,300,000 shares to 9,800,000 shares.
|
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
|
45,530,046
|
20,250,932
|
44,002
|
9,282,793
|
appointment of KPMG LLP as the Companys independent registered
public accounting firm for the fiscal year ending December 31,
2017.
|
Votes For
|
Votes Against
|
Votes Abstaining
|
Broker Non-Votes
|
|
70,274,258
|
4,830,508
|
3,007
|
—
|
Form 8-K:
|
Exhibit No.
|
Description
|
|
|
10.1
|
2015 Stock Incentive Plan, as amended
|
About ENDOLOGIX, INC. (NASDAQ:ELGX)
Endologix, Inc. is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens. The EVAR products include the Endologix AFX Endovascular AAA System (AFX), the VELA Proximal Endograft (VELA) and the Endologix Powerlink with Intuitrak Delivery System (Intuitrak). The EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). Its EVAS product is the Nellix EndoVascular Aneurysm Sealing System (Nellix EVAS System). It offers accessories to facilitate the optimal delivery of its EVAR products, including compatible guidewires, snares, and catheter introducer sheaths. ENDOLOGIX, INC. (NASDAQ:ELGX) Recent Trading Information
ENDOLOGIX, INC. (NASDAQ:ELGX) closed its last trading session down -0.06 at 4.95 with 2,134,006 shares trading hands.